Clinical Trial Update: EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) [Phase 1, Phase 2]

View source ↗

Summary

Grey Wolf Therapeutics is recruiting for EAST-1, a Phase 1/2 trial of an ERAP inhibitor for axial spondyloarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• EAST-1 ERAP inhibitor (ERAP inhibitor)

Snippet

Sponsor: Grey Wolf Therapeutics | Conditions: Axial Spondyloarthritis (AxSpA) | Phase 1, Phase 2 | Status: RECRUITING